NASDAQ · ILMN

Illumina Inc.

$194.09 -$2.77 (-1.41%) 1D After hours
Session Pulse Overnight session 1 mentions on Fri · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 7/11 this week Full pulse →
Charting by TradingView

Key Metrics

$29.78B
Market cap
34.92×
P/E · TTM
$4.39B
Revenue · TTM
$853.00M
Net income
EPS · TTM $5.36
Dividend yield —
Free cash flow $974.00M
Beta · 1Y 0.92
EBITDA · TTM $1.31B
Gross margin 66.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    Money has been moving out of its sector (Technology).

    Technology has run -4.1 points vs SPY over four weeks, ranking 8→2→11→7 of 11 sectors — this stock trades inside that current.

    RECEIPT: ROTATION MAP, LIVE ↗
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 6
    The stock moved -10.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$29.78B
Enterprise value—
Shares outstanding151.3M
52-wk range$88.00 – $199.14
Avg volume · 20D1.6M
Net cash —
Book value / share$16.83
IndustryLaboratory Analytical Instruments
ExchangeNASDAQ
About Illumina Inc.
IPO dateJul 28, 2000
Employees8650

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E34.92
P/S6.78
P/FCF30.58
EV/EBITDA—
EV/Sales—
Graham №$45.07

Profitability

Gross 66.2%
Operating 24.2%
Net 19.4%
FCF 22.2%
ROE / ROIC 33.8% · 32.7%

Financial Health

Current ratio1.75
Quick ratio1.36
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$1.17B

Cash Flow · TTM

Operating CF $1.13B
Capex −$154.00M
Free cash flow $974.00M
Buybacks $784.00M
Dividends paid —
Shareholder yield 2.6%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$45.07 vs $194.09
Trades 4.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-29 · computed by TickerWolf from SEC filings